Chronic obstructive pulmonary disease (COPD) is the most common chronic tract disease and the third leading cause of death worldwide. The treatment effect of COPD is poor, and the disease is progressive, resulting in a serious disease burden. The key reason is that early recognition is difficult and the early pathophysiological mechanism is unclear, which leads to the difficulty of early intervention.PRISm is likely to be the precursor stage of COPD, which may provide an important research object for the study of pathophysiological characteristics, inflammation and immunomodulatory mechanisms of early COPD, and may also become a new entry point for early intervention of COPD. This study attempts to establish a PRISm prospective cohort,and collects blood, EBC and urine for analysis of inflammatory factors, metabolomics, proteomics and microbiome, and performs chest HRCT to obtain imaging indicators, and conducts 3-year dynamic follow-up observation to study the evolution characteristics of pulmonary function and the incidence of COPD in the PRISm cohort. To compare the differences in imaging, inflammatory factors, metabolomics, proteomics and microbiome among the three PRISm groups, and establish a risk prediction model for progression to COPD through PRISm. It lays a foundation for understanding the characteristics of COPD at an earlier stage and exploring new early warning indicators.
Study Type
OBSERVATIONAL
Enrollment
2,000
Peking University First Hospital
Beijing, Beijing Municipality, China
RECRUITINGPeking University First Hospital
Beijing, Beijing Municipality, China
RECRUITINGThe First Hospital of Qinhuangdao
Qinhuangdao, Hebei, China
RECRUITINGTianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
RECRUITINGShandong Provincial Hospital Affiliated to Shandong University
Jing’an, China
RECRUITINGShanxi Bethune Hospital
Taiyuan, China
RECRUITINGThe number and proportion of newly diagnosed COPD
FEV1/FVC\<0.7 after bronchodilator inhalation during 3 years of follow-up
Time frame: the third year of follow-up
The number and proportion of continuous PRISm population
After bronchodilator inhalation, FEV1/FVC≥70% and the percentage of FEV1pred%\<80% during 3 years of follow-up
Time frame: the third year of follow-up
The number and proportion of PRISm to normal population
After bronchodilator inhalation, FEV1/FVC≥0.7 and FEV1pred% ≥80% during 3 years of follow-up
Time frame: the third year of follow-up
Emerging diseases
Emerging diseases: non-COPD lung diseases (bronchial asthma, ILD), OSA, cardiovascular diseases (such as coronary heart disease, hypertension, etc.), endocrine diseases (such as diabetes), cerebrovascular diseases, digestive diseases, chronic kidney diseases, etc.
Time frame: the third year of follow-up
Death and cause of death
Death and cause of death
Time frame: the third year of follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.